...
首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer
【24h】

Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer

机译:透明质酸装饰Pluronic P85固体脂质纳米粒子作为潜在的载体,以克服宫颈和乳腺癌的多药耐药性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

This work aimed to develop hyaluronic acid (HA) decorated pluronic 85 (P85) coated solid lipid nanoparticles (SLN) loaded with paclitaxel (HA-PTX-P85-SLN) and to evaluate its potential to overcome drug resistance and to increase antitumor efficacy in mice bearing cervical and breast tumor. P85-Distearoyl Phosphoethanolamine (DSPE) was synthesized from P85 and DSPE by coupling in the presence of 1,10-carbonyldiimidazole (CDI) as a catalyst. The SLN were prepared by the hot homogenization technique and electrostatic interaction. PTX-loaded SLN was characterized for mean diameter, zeta potential, morphology, entrapment efficiency (EE), drug loading capacity (LC) and in vitro drug release. In vivo animal evaluation containing antitumor effect, pharmacokinetics and biodistribution were conducted in mice bearing cervical and breast tumor. The HA-PTX-P85-SLN showed a mean diameter of 160.3 nm, negative zeta potential (-31.6 mV), EE of 88.2%, and LC of 4.9%. PTX from HA-PTX-P85-SLN exhibited greater sustained drug release profiles compared free PTX. Pharmacokinetics results indicated that HA-PTX-P85-SLN exhibited a 5.5-fold increase in AUC in comparison to free PTX. Biodistribution results revealed that HA-PTX-P85-SLN exhibited higher tumor drug concentration compared with free PTX. (C) 2016 Elsevier Masson SAS. All rights reserved.
机译:这种作品旨在开发透明质酸(HA)装饰的Pluronic 85(P85)涂覆的固体脂质纳米颗粒(SLN),其装有紫杉醇(HA-PTX-P85-SLN)并评估其克服耐药性并增加抗肿瘤功效的可能性并增加抗肿瘤效果患宫颈和乳腺肿瘤的小鼠。通过在1,10-羰基二咪唑(CDI)作为催化剂的存在下,通过偶联了P85- Distearoyl磷酸乙醇胺(DSPE)。通过热均化技术和静电相互作用制备SLN。加载PTX的SLN的特征在于平均直径,Zeta电位,形态,夹带效率(EE),药物负载能力(LC)和体外药物释放。在含有抗肿瘤效应的体内动物评估中,药代动力学和生物分布是在患有宫颈和乳腺肿瘤的小鼠中进行的。 HA-PTX-P85-SLN显示平均直径为160.3nm,阴性Zeta电位(-31.6mV),EE为88.2%,LC为4.9%。 HA-PTX-P85-SLN的PTX表现出更大的持续的药物释放曲线FIRE PTX。药代动力学结果表明,与游离PTX相比,HA-PTX-P85-SLN呈现5.5倍的AUC增加。生物分布结果显示,与游离PTX相比,HA-PTX-P85-SLN表现出更高的肿瘤药物浓度。 (c)2016 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号